Recurrence of Hyperprolactinemia Following Dopamine Agonist Withdrawal and Possible Predictive Factors of Recurrence in Prolactinomas.

E. Sala, P. Bellaviti Buttoni,E. Malchiodi,E. Verrua,G. Carosi,E. Profka,G. Rodari,M. Filopanti,E. Ferrante,A. Spada,G. Mantovani

Journal of endocrinological investigation（2016）

引用 24|浏览0

暂无评分

摘要

The optimal duration of cabergoline (CAB) treatment of prolactinomas that minimizes recurrences is not well established. 2011 Endocrine Society Guidelines suggested that withdrawal may be safely undertaken after 2 years in patients achieving normoprolactinemia and tumor reduction.

查看译文

关键词

Prolactinomas,Hyperprolactinemia,Dopamine agonist therapy,Pituitary adenoma,Recurrence

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要